Oncology

News

ASCO: Conversational AI tackles missed colonoscopies

An artificial intelligence-based tool has shown impressive results in raising colorectal cancer screening rates in underserved populations.

News

ASCO: Novartis’ Scemblix aces first-line CML study

Novartis’ first-in-class STAMP inhibitor Scemblix could be headed for use earlier in the treatment pathway for chronic myeloid leukaemia (CML).

News

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer.

News

Lilly’s Retevmo cleared for RET-positive child cancers

The US FDA has given accelerated approval for Eli Lilly’s RET inhibitor as a treatment for various RET-altered paediatric cancers, making it the first drug in the class av

News

FDA sets date for Sarclisa in first-line multiple myeloma

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority revi

News

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

The overall survival (OS) data has come in from the TROPION-Lung01 study of AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in lung cancer – and the res

ASCO: Conversational AI tackles missed colonoscopies

ASCO: Novartis’ Scemblix aces first-line CML study

Gilead’s Trodelvy woes rise with failed bladder cancer trial

Lilly’s Retevmo cleared for RET-positive child cancers

FDA sets date for Sarclisa in first-line multiple myeloma

AZ’s Dato-DXd misses survival endpoint in lung cancer trial

Sanofi swoops on Dynavax with $2.5bn takeover deal

How to meet your physicians where they are online

Oncology

Editor's Picks